Centanafadine is the first ADHD medication in development that targets all three of the neurotransmitters most implicated in attention — norepinephrine, dopamine, and serotonin — in a single molecule. Developed by Otsuka Pharmaceuticals, it's an investigational, non-stimulant compound that represents a genuinely new mechanism of action. Otsuka has submitted a New Drug Application (NDA) to the U.S. FDA for the treatment of ADHD in children, adolescents, and adults. It is not yet approved, and it is not available to patients.
This is a meaningful development, because for decades the pharmacology of ADHD has been dominated by two levers. Here's what's new, why it matters, and what patients should — and shouldn't — expect.
What centanafadine is
Centanafadine (sometimes abbreviated CTN) is a first-in-class norepinephrine–dopamine–serotonin reuptake inhibitor, or NDSRI. In plain terms, it's a "triple reuptake inhibitor": it slows the brain's reabsorption of three neurotransmitters at once, leaving more of each active in the synapse for longer.
It is a non-stimulant. That distinction matters. The medications most associated with ADHD — methylphenidate and amphetamine-based stimulants — work primarily by driving up dopamine and norepinephrine. They're effective, but they're also controlled substances, with the tolerability and regulatory baggage that implies. Centanafadine takes a different route to a related goal.
The three neurotransmitters behind ADHD
To understand why a triple reuptake inhibitor is interesting, it helps to understand what each of these three chemicals actually does in the brain.
Norepinephrine — signal and alertness
Norepinephrine is the brain's "signal booster." It sharpens attention, regulates arousal, and helps you filter what matters from what doesn't. When norepinephrine signaling is too low, the world feels noisy and indistinct — you're alert but can't lock on. Most non-stimulant ADHD medications in use today (like atomoxetine) work primarily on this system.
Dopamine — motivation and follow-through
Dopamine is the molecule of reward, motivation, and follow-through. It's what makes a task feel worth starting — and worth finishing. Low dopamine signaling is the neurochemical signature behind the classic ADHD experience: you can do the thing you find fascinating, and you cannot make yourself do the thing that bores you, no matter how much you care about the outcome. Stimulants target this system hard.
Serotonin — mood, impulse, and the missing piece
Serotonin is the part of the picture that current ADHD medications largely ignore. It regulates mood, impulse control, sleep, and emotional reactivity. This is the gap centanafadine is built to fill. Stimulants have minimal effect on serotonin; centanafadine has a more pronounced one — and that's the core of its promise.
Why a triple reuptake inhibitor is different
Most ADHD treatment today is a choice between two profiles:
- Stimulants — strong on dopamine and norepinephrine, weak on serotonin. Effective for focus, but with appetite, sleep, and rebound effects, and the constraints of being a controlled substance.
- Non-stimulants (atomoxetine, guanfacine, viloxazine) — gentler, not controlled, but typically narrower in effect and slower to work.
Centanafadine sits in a new place: a non-stimulant that addresses all three systems, including the serotonergic dimension that touches mood and impulsivity. The hypothesis is that by engaging serotonin alongside norepinephrine and dopamine, it could help with the parts of ADHD that focus medications leave untouched — emotional dysregulation, impulsivity, and the mood instability that travels alongside ADHD in many adults.
What the clinical data show so far
Centanafadine has been studied in Phase 3 trials in children, adolescents, and adults. Across these studies, it demonstrated statistically significant improvement in ADHD symptoms compared to placebo, measured by standard rating scales such as the ADHD Rating Scale.
The tolerability profile reported in trials is distinct from the stimulant profile. The most common side effects were gastrointestinal (nausea, decreased appetite) and effects on sleep, rather than the classic stimulant jitter or crash. As with any investigational compound, the full safety picture will only become clear with broader, real-world use after approval — if it comes.
A caveat worth stating plainly: this is investigational data. Results in trials don't always translate perfectly to everyday clinical practice, and the evidence continues to evolve as the FDA review proceeds.
Where it is in the approval process
Otsuka has submitted a New Drug Application to the FDA. That submission triggers a formal review period during which the agency evaluates the evidence for efficacy and safety. If approved, centanafadine would become the first triple reuptake inhibitor available for ADHD — and a new non-stimulant option in a field that hasn't seen a genuinely new mechanism in years.
It is not available now. No clinician can prescribe it, and no patient can take it. Any claim that centanafadine is being offered today is not accurate.
What this means for patients today
If you're managing ADHD now, centanafadine doesn't change your options yet. The current toolkit — stimulants, non-stimulants, therapy, and the lifestyle and neurochemical work that supports all of it — remains what's available.
What centanafadine could change, if approved, is the landscape for people who:
- Don't respond adequately to stimulants or existing non-stimulants
- Can't tolerate stimulant side effects or have contraindications
- Have ADHD complicated by mood instability, anxiety, or impulsivity that the focus medications don't fully address
- Prefer a non-controlled option
More options matter in psychiatry, because ADHD is heterogeneous. Two people with the same diagnosis can have very different neurochemical profiles, and the medication that transforms one person's life can do nothing for the next. A new mechanism doesn't replace what works — it widens the menu.
The bottom line
Centanafadine is a genuine pharmacological advance in development: a non-stimulant that, for the first time, targets the serotonergic dimension of ADHD alongside dopamine and norepinephrine. The data so far are encouraging, the NDA is filed, and the field is watching.
But it is not here yet. If you're struggling with focus, follow-through, or the emotional undercurrents of ADHD, you don't have to wait for a new drug to get good care — a careful evaluation and the options available today can make a real difference now. We'll be covering centanafadine's approval status as it develops.